Save Product
Product Details
Synonyms
TNFRSF8, CD30, D1S166E, Ki-1
Source
Human CD30 Protein, Llama IgG2b Fc Tag (TN8-H5250) is expressed from human 293 cells (HEK293). It contains AA Phe 19 - Lys 379 (Accession # NP_001234.2).
Predicted N-terminus: Phe 19
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a llama IgG2b Fc tag at the C-terminus.
The protein has a calculated MW of 66.3 kDa. The protein migrates as 95-120 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 0.01 EU per μg by the LAL method / rFC method.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human CD30 Protein, Llama IgG2b Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized Human CD30 Protein, Llama IgG2b Fc Tag (Cat. No. TN8-H5250) at 0.5 μg/mL (100 μL/well) can bind Anti-CD30 Mab, Human IgG1 with a linear range of 0.1-1.6 ng/mL (QC tested).
Protocol
Bioactivity-BLI
Loaded Human CD30 Ligand, His Tag (Cat. No. CDL-H524b) on HIS1K Biosensor, can bind Human CD30 Protein, Llama IgG2b Fc Tag (Cat. No. TN8-H5250) with an affinity constant of 55.5 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Tumor necrosis factor receptor superfamily member 8
- Category：
- Approved Drugs：
1 Details
- Drugs in Clinical Trials：
22 Details
- Highest Development Stage：
Approved
Contact Us
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
Drug Candidate Licensing
